Cargando…

Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis

Osteoarthritis drugs are often short-acting; therefore, to enhance their efficacy, long-term, stable-release, drug-delivery systems are urgently needed. Mesoporous polydopamine (MPDA), a natural nanoparticle with excellent biocompatibility and a high loading capacity, synthesized via a self-aggregat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yun, Ge, Weiwen, Ma, Zhigui, Ji, Guangyu, Wang, Mingsong, Zhou, Guangdong, Wang, Xiansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AIP Publishing LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033307/
https://www.ncbi.nlm.nih.gov/pubmed/35496642
http://dx.doi.org/10.1063/5.0088447
_version_ 1784692855950802944
author Wang, Yun
Ge, Weiwen
Ma, Zhigui
Ji, Guangyu
Wang, Mingsong
Zhou, Guangdong
Wang, Xiansong
author_facet Wang, Yun
Ge, Weiwen
Ma, Zhigui
Ji, Guangyu
Wang, Mingsong
Zhou, Guangdong
Wang, Xiansong
author_sort Wang, Yun
collection PubMed
description Osteoarthritis drugs are often short-acting; therefore, to enhance their efficacy, long-term, stable-release, drug-delivery systems are urgently needed. Mesoporous polydopamine (MPDA), a natural nanoparticle with excellent biocompatibility and a high loading capacity, synthesized via a self-aggregation-based method, is frequently used in tumor photothermal therapy. Here, we evaluated its efficiency as a sustained and controlled-release drug carrier and investigated its effectiveness in retarding drug clearance. To this end, we used MPDA as a controlled-release vector to design a drug-loaded microsphere system (RCGD423@MPDA) for osteoarthritis treatment, and thereafter, tested the efficacy of the system in a rat model of osteoarthritis. The results indicated that at an intermediate drug-loading dose, MPDA showed high drug retention. Furthermore, the microsphere system maintained controlled drug release for over 28 days. Our in vitro experiments also showed that drug delivery using this microsphere system inhibited apoptosis-related cartilage degeneration, whereas MPDA-only administration did not show obvious cartilage degradation improvement effect. Results from an in vivo osteoarthritis model also confirmed that drug delivery via this microsphere system inhibited cartilage damage and proteoglycan loss more effectively than the non-vectored drug treatment. These findings suggest that MPDA may be effective as a controlled-release carrier for inhibiting the overall progression of osteoarthritis. Moreover, they provide insights into the selection of drug-clearance retarding vectors, highlighting the applicability of MPDA in this regard.
format Online
Article
Text
id pubmed-9033307
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AIP Publishing LLC
record_format MEDLINE/PubMed
spelling pubmed-90333072022-04-29 Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis Wang, Yun Ge, Weiwen Ma, Zhigui Ji, Guangyu Wang, Mingsong Zhou, Guangdong Wang, Xiansong APL Bioeng Articles Osteoarthritis drugs are often short-acting; therefore, to enhance their efficacy, long-term, stable-release, drug-delivery systems are urgently needed. Mesoporous polydopamine (MPDA), a natural nanoparticle with excellent biocompatibility and a high loading capacity, synthesized via a self-aggregation-based method, is frequently used in tumor photothermal therapy. Here, we evaluated its efficiency as a sustained and controlled-release drug carrier and investigated its effectiveness in retarding drug clearance. To this end, we used MPDA as a controlled-release vector to design a drug-loaded microsphere system (RCGD423@MPDA) for osteoarthritis treatment, and thereafter, tested the efficacy of the system in a rat model of osteoarthritis. The results indicated that at an intermediate drug-loading dose, MPDA showed high drug retention. Furthermore, the microsphere system maintained controlled drug release for over 28 days. Our in vitro experiments also showed that drug delivery using this microsphere system inhibited apoptosis-related cartilage degeneration, whereas MPDA-only administration did not show obvious cartilage degradation improvement effect. Results from an in vivo osteoarthritis model also confirmed that drug delivery via this microsphere system inhibited cartilage damage and proteoglycan loss more effectively than the non-vectored drug treatment. These findings suggest that MPDA may be effective as a controlled-release carrier for inhibiting the overall progression of osteoarthritis. Moreover, they provide insights into the selection of drug-clearance retarding vectors, highlighting the applicability of MPDA in this regard. AIP Publishing LLC 2022-04-21 /pmc/articles/PMC9033307/ /pubmed/35496642 http://dx.doi.org/10.1063/5.0088447 Text en © 2022 Author(s). https://creativecommons.org/licenses/by/4.0/All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Articles
Wang, Yun
Ge, Weiwen
Ma, Zhigui
Ji, Guangyu
Wang, Mingsong
Zhou, Guangdong
Wang, Xiansong
Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
title Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
title_full Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
title_fullStr Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
title_full_unstemmed Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
title_short Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
title_sort use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033307/
https://www.ncbi.nlm.nih.gov/pubmed/35496642
http://dx.doi.org/10.1063/5.0088447
work_keys_str_mv AT wangyun useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis
AT geweiwen useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis
AT mazhigui useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis
AT jiguangyu useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis
AT wangmingsong useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis
AT zhouguangdong useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis
AT wangxiansong useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis